Avidian Wealth Enterprises LLC Buys Shares of 5,978 Enovis Co. (NYSE:ENOV)

Avidian Wealth Enterprises LLC purchased a new position in shares of Enovis Co. (NYSE:ENOV) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 5,978 shares of the company’s stock, valued at approximately $262,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. River Road Asset Management LLC purchased a new stake in Enovis in the third quarter valued at $51,341,000. Royce & Associates LP raised its holdings in Enovis by 16.8% in the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock valued at $103,479,000 after buying an additional 346,317 shares during the period. Diamond Hill Capital Management Inc. lifted its position in Enovis by 7.8% in the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company’s stock valued at $129,352,000 after buying an additional 218,660 shares during the last quarter. Artemis Investment Management LLP boosted its stake in Enovis by 35.4% during the fourth quarter. Artemis Investment Management LLP now owns 665,868 shares of the company’s stock worth $29,218,000 after buying an additional 174,116 shares during the period. Finally, DAVENPORT & Co LLC increased its position in shares of Enovis by 6.0% during the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock valued at $121,181,000 after acquiring an additional 157,216 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Trading Up 0.4 %

NYSE ENOV opened at $43.89 on Friday. Enovis Co. has a one year low of $38.27 and a one year high of $65.03. The firm has a 50 day simple moving average of $45.37 and a 200-day simple moving average of $44.40. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -20.04 and a beta of 1.94. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a “buy” rating and issued a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $64.83.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.